Literature DB >> 16114026

Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.

Inger Marie Skogseid1, Jo Røislien, Bjørgulf Claussen, Emilia Kerty.   

Abstract

We examined the impact of cervical dystonia (CD) and long-term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long-term treatment were obtained from 62 CD patients aged 31-66 years (median, 53 years; 61% females) who had been treated for a median of 5 years (range, 1.5-10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long-term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16114026     DOI: 10.1002/mds.20670

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

1.  Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia.

Authors:  Andre C Felicio; Clecio Godeiro-Junior; Patricia de Carvalho Aguiar; Vanderci Borges; Sonia M A Silva; Henrique B Ferraz
Journal:  Neurol Sci       Date:  2009-05-26       Impact factor: 3.307

2.  Head tremor and pain in cervical dystonia.

Authors:  Jeanne P Vu; Ha Yeon Lee; Qiyu Chen; Elizabeth Cisneros; Richard L Barbano; Christopher G Goetz; Joseph Jankovic; Hyder A Jinnah; Joel S Perlmutter; Brian D Berman; Mark I Appelbaum; Glenn T Stebbins; Cynthia L Comella; David A Peterson
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 4.849

Review 3.  Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value.

Authors:  E Zoons; M G W Dijkgraaf; J M Dijk; I N van Schaik; M A Tijssen
Journal:  J Neurol       Date:  2012-05-03       Impact factor: 4.849

4.  Repetitive transcranial magnetic stimulation in cervical dystonia: effect of site and repetition in a randomized pilot trial.

Authors:  Sarah Pirio Richardson; Sule Tinaz; Robert Chen
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

5.  AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.

Authors:  Seye Abogunrin; Sarah Brand; Kamal Desai; Jerome Dinet; Sylvie Gabriel; Timothy Harrower
Journal:  Clinicoecon Outcomes Res       Date:  2015-09-09

6.  An international survey of patients with cervical dystonia.

Authors:  Cynthia Comella; Kailash Bhatia
Journal:  J Neurol       Date:  2015-01-22       Impact factor: 4.849

7.  Exploring factors related to physical activity in cervical dystonia.

Authors:  Lena Zetterberg; Charlotte Urell; Elisabeth Anens
Journal:  BMC Neurol       Date:  2015-12-01       Impact factor: 2.474

8.  Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry.

Authors:  Eric S Molho; Mark Stacy; Patrick Gillard; David Charles; Charles H Adler; Joseph Jankovic; Marc Schwartz; Mitchell F Brin
Journal:  Mov Disord Clin Pract       Date:  2015-12-16

Review 9.  Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.

Authors:  Alberto Albanese; Giovanni Abbruzzese; Dirk Dressler; Wojciech Duzynski; Svetlana Khatkova; Maria Jose Marti; Pablo Mir; Cesare Montecucco; Elena Moro; Michaela Pinter; Maja Relja; Emmanuel Roze; Inger Marie Skogseid; Sofiya Timerbaeva; Charalampos Tzoulis
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

10.  Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data.

Authors:  Hsin Fen Chien; Ana Lucia Zuma de Rosso; André Sobierajski Dos Santos; Carlos Roberto de Mello Rieder; Debora Palma Maia; Delson José da Silva; Marcio da Cunha Andrade; Marcus Vinicius Della Coletta; Maria do Desterro Leiros da Costa; Nasser Allam; Roberto César Pereira do Prado; Vanderci Borges; Vitor Tumas; Wagner de Goes Horta
Journal:  eNeurologicalSci       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.